QGEN
Qiagen N.V.
Price Chart
Latest Quote
$36.95
+0.37 (+1.01%)
Current Price
| Previous Close | $36.58 |
| Open | $36.24 |
| Day High | $37.06 |
| Day Low | $36.19 |
| Volume | 1,442,935 |
Stock Information
| Quarterly Dividend / Yield | $0.35 / 0.95% |
| Shares Outstanding | 206.25M |
| Quarterly Dividend Yield | 0.95% |
| Quarterly Dividend | $0.35 |
| Total Debt | $1.67B |
| Cash Equivalents | $646.29M |
| Revenue | $2.10B |
| Net Income | $402.16M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $7.62B |
| P/E Ratio | 18.85 |
| EPS (TTM) | $1.96 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.64B |
| Sales | $2.10B |
| Income | $402.16M |
| Book/sh | $16.15 |
| Cash/sh | $3.13 |
| Employees | 6K |
Financial Ratios
| Quick Ratio | 2.21 |
| Current Ratio | 3.21 |
| Debt/Eq | 50.04 |
| EPS Growth TTM | -25.00% |
Returns & Margins
| ROA | 6.01% |
| ROE | 11.93% |
| Gross Margin | 66.14% |
| Operating Margin | 23.82% |
| Profit Margin | 19.16% |
Ownership
| Insider Ownership | 0.47% |
| Institutional Ownership | 83.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.01 |
| PEG | 0.93 |
| P/S | 3.63 |
| P/B | 2.29 |
Analyst Data
| Recommendation | buy |
| Target Price | $43.82 |
Technical Indicators
| SMA20 | $36.54 |
| SMA50 | $36.59 |
| SMA200 | $43.97 |
| RSI | 52.15 |
| ATR | 1.0043 |
| Shares Float | 204.79M |
| Short Float | 3.16% |
| Short Ratio | 2.42 |
| Volatility | 0.66 |
| Rel Volume | 0.91 |
Performance History
| Week | -1.26% |
| Month | +7.91% |
| Quarter | -9.10% |
| 6 Months | -17.91% |
| YTD | -18.23% |
| Year | -20.21% |
| 3 Years | -19.74% |
| 5 Years | -22.49% |
| 10 Years | +76.50% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $36.95 | 1,964,100 |
| 2026-06-17 | $36.58 | 2,823,900 |
| 2026-06-16 | $37.22 | 2,117,200 |
| 2026-06-15 | $37.01 | 2,511,600 |
| 2026-06-12 | $37.06 | 1,894,700 |
| 2026-06-11 | $37.42 | 2,623,300 |
| 2026-06-10 | $37.02 | 2,488,200 |
| 2026-06-09 | $37.75 | 2,159,400 |
| 2026-06-08 | $36.23 | 1,485,800 |
| 2026-06-05 | $36.68 | 1,412,900 |
| 2026-06-04 | $37.56 | 2,865,900 |
| 2026-06-03 | $36.45 | 3,248,200 |
| 2026-06-02 | $35.69 | 2,442,600 |
| 2026-06-01 | $36.18 | 1,958,200 |
| 2026-05-29 | $36.59 | 3,046,500 |
| 2026-05-28 | $36.64 | 2,096,100 |
| 2026-05-27 | $36.13 | 2,252,600 |
| 2026-05-26 | $35.54 | 1,532,800 |
| 2026-05-22 | $35.17 | 1,197,000 |
| 2026-05-21 | $34.89 | 1,233,700 |
| 2026-05-20 | $35.09 | 1,647,600 |
| 2026-05-19 | $34.24 | 2,595,900 |
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
đ° Latest News
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
Zacks âĸ 2026-06-15T15:16:00Z
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-05T15:30:27Z
Agilent Technologies (A) Declined in Q1 Amid QIAGEN Acquisition Speculation
Insider Monkey âĸ 2026-06-03T13:51:49Z
Evaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price Recovery
Simply Wall St. âĸ 2026-06-01T11:12:53Z
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
Zacks âĸ 2026-05-29T13:16:00Z
QIAGEN Business Breakdown and Growth Drivers for 2026
Zacks âĸ 2026-05-28T13:57:00Z
NVIDIA Qiagen Alliance Extends AI Reach Into Drug Discovery Workflows
Simply Wall St. âĸ 2026-05-21T13:15:14Z
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
Zacks âĸ 2026-05-20T12:37:00Z
3 Stocks in Focus That Recently Declared Dividend Hikes Amid High Inflation
Zacks âĸ 2026-05-20T12:33:00Z
QIAGEN and NVIDIA partner on AI drug discovery
Pharmaceutical Technology âĸ 2026-05-20T10:22:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $604,758,000 | $817,192,000 | $537,051,000 | $563,089,000 |
| Cost Of Revenue | $790,504,000 | $1,010,864,000 | $731,623,000 | $756,955,000 |
| Total Revenue | $2,089,999,000 | $1,978,214,000 | $1,965,311,000 | $2,141,518,000 |
| Operating Revenue | $2,089,999,000 | $1,978,214,000 | $1,965,311,000 | $2,141,518,000 |
| Expenses | ||||
| Interest Expense | $33,256,000 | $43,841,000 | $53,410,000 | $58,357,000 |
| Total Expenses | $1,569,689,000 | $1,778,315,000 | $1,520,064,000 | $1,565,290,000 |
| Other Income Expense | $-61,109,000 | $-102,927,000 | $-41,020,000 | $-38,027,000 |
| Other Non Operating Income Expenses | $-6,650,000 | $-739,000 | $-5,711,000 | $6,741,000 |
| Net Non Operating Interest Income Expense | $31,064,000 | $24,175,000 | $25,582,000 | $-25,600,000 |
| Interest Expense Non Operating | $33,256,000 | $43,841,000 | $53,410,000 | $58,357,000 |
| Operating Expense | $779,185,000 | $767,451,000 | $788,441,000 | $808,335,000 |
| Selling And Marketing Expense | $457,993,000 | $450,929,000 | $459,912,000 | $474,220,000 |
| General And Administrative Expense | $125,676,000 | $113,432,000 | $119,254,000 | $129,725,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Net Interest Income | $31,064,000 | $24,175,000 | $25,582,000 | $-25,600,000 |
| Interest Income | $64,320,000 | $68,016,000 | $78,992,000 | $32,757,000 |
| Normalized Income | $472,095,953 | $154,100,720 | $369,338,346 | $460,189,368 |
| Net Income From Continuing And Discontinued Operation | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Total Operating Income As Reported | $465,851,000 | $97,711,000 | $409,938,000 | $531,460,000 |
| Net Income Common Stockholders | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Net Income | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Net Income Including Noncontrolling Interests | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Net Income Continuous Operations | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Pretax Income | $490,265,000 | $121,147,000 | $429,809,000 | $512,601,000 |
| Special Income Charges | $-54,459,000 | $-102,188,000 | $-35,309,000 | $-44,768,000 |
| Interest Income Non Operating | $64,320,000 | $68,016,000 | $78,992,000 | $32,757,000 |
| Operating Income | $520,310,000 | $199,899,000 | $445,247,000 | $576,228,000 |
| Depreciation Amortization Depletion Income Statement | $8,000,000 | $9,596,000 | $10,764,000 | $14,531,000 |
| Depreciation And Amortization In Income Statement | $8,000,000 | $9,596,000 | $10,764,000 | $14,531,000 |
| Amortization Of Intangibles Income Statement | $8,000,000 | $9,596,000 | $10,764,000 | $14,531,000 |
| Gross Profit | $1,299,495,000 | $967,350,000 | $1,233,688,000 | $1,384,563,000 |
| Per Share | ||||
| Diluted EPS | $2.04 | $0.40 | $1.65 | $2.79 |
| Basic EPS | $2.06 | $0.41 | $1.67 | $2.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $-7,243,047 | $-31,678,280 | $-7,273,654 | $-7,789,632 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $771,726,000 | $470,444,000 | $723,864,000 | $824,123,000 |
| Total Unusual Items | $-54,459,000 | $-102,188,000 | $-35,309,000 | $-44,768,000 |
| Total Unusual Items Excluding Goodwill | $-54,459,000 | $-102,188,000 | $-35,309,000 | $-44,768,000 |
| Reconciled Depreciation | $193,746,000 | $203,268,000 | $205,336,000 | $208,397,000 |
| EBITDA (Bullshit earnings) | $717,267,000 | $368,256,000 | $688,555,000 | $779,355,000 |
| EBIT | $523,521,000 | $164,988,000 | $483,219,000 | $570,958,000 |
| Diluted Average Shares | $207,936,000 | $207,551,118 | $206,612,202 | $206,179,481 |
| Basic Average Shares | $206,074,698 | $205,309,513 | $204,447,482 | $203,886,866 |
| Diluted NI Availto Com Stockholders | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Tax Provision | $65,385,000 | $37,556,000 | $88,506,000 | $89,390,000 |
| Restructuring And Mergern Acquisition | $54,459,000 | $102,188,000 | $35,309,000 | $44,768,000 |
| Amortization | $8,000,000 | $9,596,000 | $10,764,000 | $14,531,000 |
| Research And Development | $187,516,000 | $193,494,000 | $198,511,000 | $189,859,000 |
| Selling General And Administration | $583,669,000 | $564,361,000 | $579,166,000 | $603,945,000 |
| Other Gand A | $125,676,000 | $113,432,000 | $119,254,000 | $129,725,000 |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $691,065,000 | $838,106,000 | $805,211,000 | $569,246,000 |
| Total Assets | $6,281,232,000 | $5,689,622,000 | $6,115,190,000 | $6,287,735,000 |
| Total Non Current Assets | $4,286,159,000 | $3,729,769,000 | $3,967,630,000 | $3,893,783,000 |
| Other Non Current Assets | $121,978,000 | $246,925,000 | $196,957,000 | $202,894,000 |
| Goodwill And Other Intangible Assets | $3,087,089,000 | $2,729,233,000 | $3,002,553,000 | $2,897,365,000 |
| Other Intangible Assets | $386,431,000 | $303,815,000 | $526,821,000 | $544,796,000 |
| Current Assets | $1,995,073,000 | $1,959,853,000 | $2,147,560,000 | $2,393,952,000 |
| Hedging Assets Current | $2,448,000 | $23,604,000 | $43,230,000 | $111,617,000 |
| Restricted Cash | $22,530,000 | $3,246,000 | $87,666,000 | $21,083,000 |
| Prepaid Assets | $49,256,000 | $41,772,000 | $44,854,000 | $50,958,000 |
| Inventory | $301,888,000 | $279,256,000 | $398,385,000 | $357,960,000 |
| Receivables | $520,033,000 | $458,983,000 | $515,643,000 | $434,068,000 |
| Other Receivables | $53,205,000 | $45,851,000 | $53,216,000 | $28,794,000 |
| Taxes Receivable | $64,220,000 | $63,854,000 | $80,550,000 | $81,524,000 |
| Accounts Receivable | $402,608,000 | $349,278,000 | $381,877,000 | $323,750,000 |
| Allowance For Doubtful Accounts Receivable | $-19,538,000 | $-18,226,000 | $-17,296,000 | $-22,880,000 |
| Gross Accounts Receivable | $422,146,000 | $367,504,000 | $399,173,000 | $346,630,000 |
| Cash Cash Equivalents And Short Term Investments | $1,098,918,000 | $1,152,992,000 | $1,057,782,000 | $1,418,266,000 |
| Cash And Cash Equivalents | $839,005,000 | $663,555,000 | $668,084,000 | $730,669,000 |
| Cash Equivalents | $702,462,000 | $570,850,000 | $580,704,000 | $608,355,000 |
| Cash Financial | $136,543,000 | $92,705,000 | $87,380,000 | $122,314,000 |
| Financial Assets | - | $3,174,000 | $3,083,000 | $131,354,000 |
| Loans Receivable | - | - | - | $29,000 |
| Non Current Deferred Assets | - | - | - | - |
| Non Current Deferred Taxes Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $815,423,000 | $727,993,000 | $841,710,000 | $1,130,781,000 |
| Total Debt | $1,812,372,000 | $1,512,541,000 | $1,532,062,000 | $1,883,670,000 |
| Long Term Debt And Capital Lease Obligation | $1,783,535,000 | $936,323,000 | $921,824,000 | $1,471,898,000 |
| Long Term Debt | $1,654,428,000 | $839,665,000 | $921,824,000 | $1,471,898,000 |
| Current Debt And Capital Lease Obligation | $28,837,000 | $576,218,000 | $610,238,000 | $411,772,000 |
| Current Debt | - | $551,883,000 | $587,970,000 | $389,552,000 |
| Other Current Borrowings | - | $551,883,000 | $587,970,000 | $389,552,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,503,078,000 | $2,122,283,000 | $2,307,426,000 | $2,821,124,000 |
| Total Non Current Liabilities Net Minority Interest | $1,990,941,000 | $1,080,252,000 | $1,228,133,000 | $1,846,601,000 |
| Other Non Current Liabilities | $207,406,000 | $143,929,000 | $207,401,000 | $217,985,000 |
| Current Liabilities | $512,137,000 | $1,042,031,000 | $1,079,293,000 | $974,523,000 |
| Other Current Liabilities | $94,248,000 | $113,214,000 | $118,033,000 | $192,194,000 |
| Current Deferred Liabilities | $79,423,000 | $70,827,000 | $66,432,000 | $69,000,000 |
| Payables And Accrued Expenses | $309,629,000 | $281,772,000 | $284,590,000 | $301,557,000 |
| Interest Payable | $13,796,000 | $10,554,000 | $8,518,000 | $5,431,000 |
| Payables | $112,373,000 | $108,218,000 | $96,630,000 | $112,714,000 |
| Total Tax Payable | $39,717,000 | $24,946,000 | $12,475,000 | $13,980,000 |
| Income Tax Payable | $39,717,000 | $24,946,000 | $12,475,000 | $13,980,000 |
| Accounts Payable | $72,656,000 | $83,272,000 | $84,155,000 | $98,734,000 |
| Derivative Product Liabilities | - | $0 | $98,908,000 | $156,718,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $3,778,154,000 | $3,567,339,000 | $3,807,764,000 | $3,466,611,000 |
| Total Equity Gross Minority Interest | $3,778,154,000 | $3,567,339,000 | $3,807,764,000 | $3,466,611,000 |
| Stockholders Equity | $3,778,154,000 | $3,567,339,000 | $3,807,764,000 | $3,466,611,000 |
| Gains Losses Not Affecting Retained Earnings | $-377,309,000 | $-474,539,000 | $-433,830,000 | $-404,091,000 |
| Other Equity Adjustments | $-377,309,000 | $-474,539,000 | $-433,830,000 | $-404,091,000 |
| Retained Earnings | $2,748,390,000 | $2,448,122,000 | $2,456,800,000 | $2,160,173,000 |
| Other | ||||
| Treasury Shares Number | $725,800 | $1,490,708 | $2,353,097 | $2,788,945 |
| Ordinary Shares Number | $206,074,698 | $205,309,513 | $204,447,482 | $204,011,784 |
| Share Issued | $206,800,498 | $206,800,221 | $206,800,579 | $206,800,729 |
| Tangible Book Value | $691,065,000 | $838,106,000 | $805,211,000 | $569,246,000 |
| Invested Capital | $5,432,582,000 | $4,958,887,000 | $5,317,558,000 | $5,328,061,000 |
| Working Capital | $1,482,936,000 | $917,822,000 | $1,068,267,000 | $1,419,429,000 |
| Capital Lease Obligations | $157,944,000 | $120,993,000 | $22,268,000 | $22,220,000 |
| Total Capitalization | $5,432,582,000 | $4,407,004,000 | $4,729,588,000 | $4,938,509,000 |
| Treasury Stock | $31,816,000 | $74,915,000 | $133,023,000 | $160,188,000 |
| Additional Paid In Capital | $1,436,360,000 | $1,666,070,000 | $1,915,115,000 | $1,868,015,000 |
| Capital Stock | $2,529,000 | $2,601,000 | $2,702,000 | $2,702,000 |
| Common Stock | $2,529,000 | $2,601,000 | $2,702,000 | $2,702,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $129,107,000 | $96,658,000 | - | - |
| Current Deferred Revenue | $79,423,000 | $70,827,000 | $66,432,000 | $69,000,000 |
| Current Capital Lease Obligation | $28,837,000 | $24,335,000 | $22,268,000 | $22,220,000 |
| Current Accrued Expenses | $197,256,000 | $173,554,000 | $187,960,000 | $188,843,000 |
| Goodwill | $2,700,658,000 | $2,425,418,000 | $2,475,732,000 | $2,352,569,000 |
| Net PPE | $1,077,092,000 | $753,611,000 | $765,037,000 | $662,170,000 |
| Accumulated Depreciation | $-464,965,000 | $-516,324,000 | $-516,765,000 | $-502,967,000 |
| Gross PPE | $1,542,057,000 | $1,269,935,000 | $1,281,802,000 | $1,165,137,000 |
| Construction In Progress | $269,347,000 | $226,155,000 | $203,978,000 | $130,407,000 |
| Other Properties | $153,144,000 | - | - | - |
| Machinery Furniture Equipment | $682,569,000 | $637,337,000 | $668,749,000 | $646,456,000 |
| Buildings And Improvements | $409,379,000 | $381,506,000 | $382,836,000 | $362,794,000 |
| Land And Improvements | $27,618,000 | $24,937,000 | $26,239,000 | $25,480,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $169,306,000 | $153,811,000 | $212,445,000 | $174,859,000 |
| Work In Process | $78,419,000 | $72,675,000 | $94,736,000 | $85,488,000 |
| Raw Materials | $54,163,000 | $52,770,000 | $91,204,000 | $97,613,000 |
| Other Short Term Investments | $259,913,000 | $489,437,000 | $389,698,000 | $687,597,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $447,200,000 | $502,309,000 | $296,653,000 | $565,928,000 |
| Operating Activities | ||||
| Operating Cash Flow | $654,326,000 | $673,551,000 | $459,455,000 | $715,264,000 |
| Cash Flow From Continuing Operating Activities | $654,326,000 | $673,551,000 | $459,455,000 | $715,264,000 |
| Operating Gains Losses | $968,000 | $426,000 | - | $6,230,000 |
| Investing Activities | ||||
| Capital Expenditure | $-207,126,000 | $-171,242,000 | $-162,802,000 | $-149,336,000 |
| Investing Cash Flow | $-305,279,000 | $-249,229,000 | $-87,655,000 | $-726,763,000 |
| Cash Flow From Continuing Investing Activities | $-305,279,000 | $-249,229,000 | $-87,655,000 | $-726,763,000 |
| Net Other Investing Changes | $-32,163,000 | $25,414,000 | $-66,554,000 | $-9,774,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-178,976,000 | $-422,896,000 | $-433,827,000 | $-125,803,000 |
| Cash Flow From Continuing Financing Activities | $-178,976,000 | $-422,896,000 | $-433,827,000 | $-125,803,000 |
| Net Other Financing Charges | $-332,884,000 | $-315,571,000 | $-33,827,000 | $-17,252,000 |
| Cash Dividends Paid | $-54,243,000 | $0 | $0 | - |
| Common Stock Dividend Paid | $-54,243,000 | $0 | $0 | - |
| Repurchase Of Capital Stock | - | $-292,099,000 | $0 | $0 |
| Net Common Stock Issuance | - | $-292,099,000 | $163,000 | $0 |
| Issuance Of Capital Stock | - | - | $163,000 | $121,000 |
| Common Stock Issuance | - | - | $163,000 | $121,000 |
| Other | ||||
| Repayment Of Debt | $-534,167,000 | $-601,536,000 | $-436,762,000 | $-480,003,000 |
| Issuance Of Debt | $742,318,000 | $494,211,000 | $0 | $371,452,000 |
| Interest Paid Supplemental Data | $29,252,000 | $24,181,000 | $20,348,000 | $23,208,000 |
| Income Tax Paid Supplemental Data | $17,266,000 | $15,684,000 | $82,409,000 | $120,476,000 |
| End Cash Position | $839,005,000 | $663,555,000 | $668,084,000 | $730,669,000 |
| Beginning Cash Position | $663,555,000 | $668,084,000 | $730,669,000 | $880,516,000 |
| Effect Of Exchange Rate Changes | $5,379,000 | $-5,955,000 | $-558,000 | $-12,545,000 |
| Changes In Cash | $170,071,000 | $1,426,000 | $-62,027,000 | $-137,302,000 |
| Proceeds From Stock Option Exercised | $0 | $0 | $36,762,000 | $0 |
| Net Issuance Payments Of Debt | $208,151,000 | $-107,325,000 | $-436,762,000 | $-108,551,000 |
| Net Long Term Debt Issuance | $208,151,000 | $-107,325,000 | $-436,762,000 | $-108,551,000 |
| Long Term Debt Payments | $-534,167,000 | $-601,536,000 | $-436,762,000 | $-480,003,000 |
| Long Term Debt Issuance | $742,318,000 | $494,211,000 | $0 | $371,452,000 |
| Net Investment Purchase And Sale | $225,237,000 | $-103,401,000 | $291,233,000 | $-504,002,000 |
| Sale Of Investment | $597,057,000 | $584,979,000 | $1,270,551,000 | $883,083,000 |
| Purchase Of Investment | $-371,820,000 | $-688,380,000 | $-979,318,000 | $-1,387,085,000 |
| Net Business Purchase And Sale | $-291,227,000 | $0 | $-149,532,000 | $-63,651,000 |
| Purchase Of Business | $-291,227,000 | $0 | $-149,532,000 | $-63,651,000 |
| Net Intangibles Purchase And Sale | $-6,077,000 | $-4,068,000 | $-13,092,000 | $-20,112,000 |
| Purchase Of Intangibles | $-6,077,000 | $-4,068,000 | $-13,092,000 | $-20,112,000 |
| Net PPE Purchase And Sale | $-201,049,000 | $-167,174,000 | $-149,710,000 | $-129,224,000 |
| Purchase Of PPE | $-201,049,000 | $-167,174,000 | $-149,710,000 | $-129,224,000 |
| Change In Working Capital | $-34,513,000 | $135,453,000 | $-186,958,000 | $-31,881,000 |
| Change In Other Working Capital | $14,316,000 | $25,528,000 | $-7,458,000 | $-21,894,000 |
| Change In Other Current Liabilities | $38,341,000 | $4,108,000 | $-6,675,000 | $-869,000 |
| Change In Other Current Assets | $-1,712,000 | $-1,194,000 | $691,000 | $-2,025,000 |
| Change In Payables And Accrued Expense | $-51,239,000 | $-7,196,000 | $-78,000,000 | $-19,593,000 |
| Change In Accrued Expense | $-42,821,000 | $-8,642,000 | $-55,583,000 | $-17,837,000 |
| Change In Payable | $-8,418,000 | $1,446,000 | $-22,417,000 | $-1,756,000 |
| Change In Account Payable | $-8,418,000 | $1,446,000 | $-22,417,000 | $-1,756,000 |
| Change In Prepaid Assets | $3,021,000 | $14,234,000 | $4,390,000 | $58,999,000 |
| Change In Inventory | $-848,000 | $87,755,000 | $-44,787,000 | $-61,950,000 |
| Change In Receivables | $-36,392,000 | $12,218,000 | $-55,119,000 | $15,451,000 |
| Changes In Account Receivables | $-36,392,000 | $12,218,000 | $-55,119,000 | $15,451,000 |
| Other Non Cash Items | $16,472,000 | $26,819,000 | $37,785,000 | $56,433,000 |
| Stock Based Compensation | $50,400,000 | $43,627,000 | $47,100,000 | $49,507,000 |
| Asset Impairment Charge | $22,440,000 | $203,408,000 | $4,158,000 | $12,970,000 |
| Deferred Tax | $-20,067,000 | $-23,041,000 | $10,731,000 | $-9,603,000 |
| Deferred Income Tax | $-20,067,000 | $-23,041,000 | $10,731,000 | $-9,603,000 |
| Depreciation Amortization Depletion | $193,746,000 | $203,268,000 | $205,336,000 | $208,397,000 |
| Depreciation And Amortization | $193,746,000 | $203,268,000 | $205,336,000 | $208,397,000 |
| Gain Loss On Investment Securities | $968,000 | $426,000 | - | $6,230,000 |
| Net Income From Continuing Operations | $424,880,000 | $83,591,000 | $341,303,000 | $423,211,000 |
| Common Stock Payments | - | $-292,099,000 | $0 | $0 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
Fetched: 2026-06-19